MLSS - Milestone Scientific Inc Stock Price, Fair Value and News

0.70USD+0.02 (+2.94%)Market Closed

Market Summary

USD0.70+0.02

Market Closed

2.94%

MLSS Stock Price

View Fullscreen

MLSS RSI Chart

MLSS Valuation

Market Cap

54.1M

Price/Earnings (Trailing)

-7.65

Price/Sales (Trailing)

5.7

EV/EBITDA

-7.21

Price/Free Cashflow

-11.95

MLSS Price/Sales (Trailing)

MLSS Profitability

EBT Margin

-74.93%

Return on Equity

-94.66%

Return on Assets

-62.22%

Free Cashflow Yield

-8.37%

MLSS Fundamentals

MLSS Revenue

Revenue (TTM)

9.5M

Rev. Growth (Yr)

-13.43%

Rev. Growth (Qtr)

-0.52%

MLSS Earnings

Earnings (TTM)

-7.1M

Earnings Growth (Yr)

-9.19%

Earnings Growth (Qtr)

25.23%

Breaking Down MLSS Revenue

Last 7 days

4.5%

Last 30 days

22.8%

Last 90 days

2.9%

Trailing 12 Months

-32.0%

How does MLSS drawdown profile look like?

MLSS Financial Health

Current Ratio

2.97

MLSS Investor Care

Shares Dilution (1Y)

10.33%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	9.5M	0	0	0
2023	8.7M	10.0M	9.8M	9.8M
2022	10.1M	9.3M	9.4M	8.8M
2021	6.6M	8.8M	9.7M	10.3M
2020	8.3M	6.2M	5.5M	5.4M
2019	9.7M	9.6M	9.8M	8.4M
2018	9.4M	9.3M	8.1M	9.6M
2017	10.7M	10.8M	10.5M	11.3M
2016	10.3M	10.9M	11.6M	10.6M
2015	10.5M	9.7M	9.7M	9.5M
2014	10.1M	10.4M	10.5M	10.3M
2013	9.2M	9.2M	9.5M	10.0M
2012	7.9M	7.7M	8.1M	8.6M
2011	9.4M	9.1M	8.7M	8.4M
2010	0	0	0	9.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Milestone Scientific Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 23, 2024	goldman neal i	acquired	12,169	0.55	22,127	-
Apr 22, 2024	goldman neal i	acquired	30,275	0.54	56,065	-
Dec 11, 2023	goldman neal i	acquired	78,750	0.63	125,000	-
Oct 23, 2023	trombetta giandomenico	back to issuer	-1,358	0.97	-1,400	-
Oct 19, 2023	trombetta giandomenico	back to issuer	-1,900	0.95	-2,000	-
Oct 19, 2023	trombetta giandomenico	back to issuer	-17,670	0.95	-18,600	-
Oct 18, 2023	trombetta giandomenico	back to issuer	-2,760	0.92	-3,000	-
Aug 01, 2023	milligan peter j	acquired	49,999	1.08	46,296	president
Jun 28, 2023	trombetta giandomenico	acquired	100,000	0.89	112,360	-
Jun 28, 2023	casamento benedetta i	acquired	120,000	0.89	134,831	-

Which funds bought or sold MLSS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-7,880	73,380	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-17.58	-8,572	24,949	-%
May 15, 2024	Royal Bank of Canada	added	1.22	-	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-33,564	312,559	0.01%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-22.69	-5,084	11,758	-%
May 15, 2024	Mariner, LLC	unchanged	-	-8,145	75,850	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	9,798	9,798	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	30.46	1,480	9,798	-%
May 15, 2024	TOWNSQUARE CAPITAL LLC	unchanged	-	-721	6,714	-%
May 15, 2024	BARCLAYS PLC	unchanged	-	-	-	-%

Are Funds Buying or Selling MLSS?

Are funds buying MLSS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MLSS

No. of Funds

Unveiling Milestone Scientific Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 20, 2020	ginsberg debra lynn	17%	80,000	SC 13G/A

Recent SEC filings of Milestone Scientific Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
Apr 23, 2024	4	Insider Trading
Apr 22, 2024	4	Insider Trading
Apr 09, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report

Peers (Alternatives to Milestone Scientific Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Milestone Scientific Inc News

Latest updates

Milestone Scientific Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-0.5%	2,248,845	2,260,596	2,059,284	2,909,966	2,597,598	2,240,937	2,215,699	1,648,368	2,700,902	2,846,033	2,108,233	2,425,738	2,924,707	2,212,066	1,246,110	167,674	1,811,386	2,300,921	1,899,821	2,257,851	1,915,909
Gross Profit	11.0%	1,676,103	1,510,075	1,503,434	1,890,059	1,889,463	1,085,005	1,452,735	680,648	1,682,426	1,780,016	1,360,236	1,369,354	1,802,294	1,404,864	836,489	112,048	1,284,136	1,539,328	1,376,149	1,505,668	1,297,215
Operating Expenses	-10.0%	3,141,171	3,489,617	3,010,139	4,167,609	3,232,139	3,099,622	3,466,230	3,565,527	3,596,909	3,320,658	3,341,157	4,241,926	2,786,667	2,599,758	2,313,217	3,284,938	2,892,742	2,665,574	2,322,883	2,613,499	2,115,396
S&GA Expenses	-8.0%	3,035,276	3,300,597	2,823,765	3,937,281	3,074,572	2,832,996	3,283,378	3,282,322	3,115,629	3,008,767	2,968,625	4,011,672	2,749,299	2,507,909	2,275,274	3,155,630	2,748,043	2,585,466	2,314,943	2,517,970	2,109,050
R&D Expenses	-46.7%	94,211	176,906	170,478	213,647	140,347	252,992	166,191	266,560	464,466	290,167	356,179	215,420	16,444	70,762	21,438	108,170	107,480	80,108	7,940	95,529	6,346
EBITDA Margin	-6.0%	-0.73	-0.69	-0.70	-0.74	-0.92	-0.98	-0.88	-0.89	-0.79	-0.69	-0.70	-0.71	-1.04	-1.36	-	-	-	-	-	-	-
Interest Expenses	-114.7%	-3,351	22,859	30,600	48,722	23,345	27,788	28,012	3,550	-4,742	-4,756	-4,608	-4,461	-2,535	-9,353	-569	-4,062	-4,097	6,479	-2,449	-2,375	1,019
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	83.00	250	-10,717	24,717	1,250	250	-1,751	1,250	14,163	4,465
Earnings Before Taxes	26.4%	-1,440,529	-1,956,683	-1,476,105	-2,228,828	-1,319,331	-1,986,829	-1,985,483	-2,881,329	-1,919,225	-1,545,398	-1,985,529	-2,600,853	-986,908	-1,204,247	-1,477,297	-3,176,952	-1,612,703	-2,917,861	-2,848,667	-1,097,744	-779,166
EBT Margin	-5.5%	-0.75	-0.71	-0.71	-0.75	-0.94	-1.00	-0.89	-0.90	-0.80	-0.69	-0.70	-0.71	-1.05	-1.37	-	-	-	-	-	-	-
Net Income	25.2%	-1,440,529	-1,926,739	-1,466,294	-2,228,828	-1,319,331	-1,953,949	-1,971,803	-2,881,329	-1,919,225	-1,107,116	-2,043,207	-2,696,793	-985,857	-1,067,367	-1,490,989	-3,178,202	-1,612,953	-2,852,155	-2,836,976	-1,053,243	-793,195
Net Income Margin	-5.5%	-0.75	-0.71	-0.71	-0.75	-0.93	-0.99	-0.84	-0.85	-0.77	-0.66	-0.70	-0.71	-1.03	-1.35	-	-	-	-	-	-	-
Free Cashflow	3.7%	-1,200,000	-1,245,799	-1,054,396	-1,024,730	-2,004,780	-1,062,340	-1,141,295	-2,293,557	-1,507,508	-400,342	-1,565,126	-1,109,655	-973,730	-638,768	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.2%	11,351	11,372	10,584	11,151	12,273	13,702	15,278	13,702	19,065	19,810	20,077	21,060	22,641	19,571	19,946	20,964	6,375	6,556	6,243	6,788	7,962
Current Assets	0.2%	10,812	10,794	9,973	10,500	11,581	12,971	14,515	15,714	18,228	18,934	19,159	20,105	21,659	18,555	18,892	19,881	5,261	6,077	5,756	6,296	7,314
Cash Equivalents	34.5%	4,005	2,978	2,171	3,701	2,278	8,715	9,812	10,959	13,255	14,764	14,491	16,000	16,951	14,224	14,449	16,610	766	1,516	1,711	2,338	2,740
Inventory	8.4%	2,860	2,638	2,483	2,193	2,038	1,792	1,552	1,505	1,792	1,542	1,677	1,479	2,021	2,420	2,230	1,852	1,723	1,621	1,617	1,270	1,861
Net PPE	-20.0%	8.00	10.00	9.00	12.00	15.00	18.00	17.00	17.00	20.00	24.00	27.00	31.00	27.00	31.00	31.00	31.00	30.00	45.00	55.00	66.00	78.00
Liabilities	15.8%	3,890	3,359	3,591	3,450	3,021	3,696	4,098	3,837	4,299	3,594	4,049	3,491	3,604	3,464	4,101	3,995	5,887	4,928	7,647	5,951	5,235
Current Liabilities	18.2%	3,637	3,077	3,279	3,109	2,653	3,300	3,675	3,389	3,827	3,097	3,529	2,949	3,039	2,878	3,494	3,368	5,240	4,928	7,647	5,951	5,219
Shareholder's Equity	-6.9%	7,460	8,013	7,246	7,702	9,252	10,226	11,181	12,676	14,766	16,215	16,028	17,568	19,037	16,107	15,845	17,009	488	1,629	-	837	2,727
Retained Earnings	-1.2%	-124,780	-123,300	-121,400	-119,934	-117,700	-116,410	-114,400	-112,464	-109,606	-107,704	-106,582	-104,539	-101,858	-100,885	-99,806	-98,315	-95,124	-93,524	-90,660	-87,823	-86,782
Additional Paid-In Capital	0.7%	133,075	132,188	129,488	128,721	128,043	127,478	126,666	126,176	125,385	124,916	123,590	123,076	121,848	117,935	116,577	116,200	96,554	96,082	90,166	89,560	90,399
Shares Outstanding	1.0%	76,602	75,849	70,860	70,074	69,306	69,273	70,481	70,357	69,013	68,120	69,574	69,221	66,578	64,138	-	-	-	-	-	-	-
Minority Interest	-	-	-	-253	-243	-230	-219	-206	-192	-170	-152	-135	-123	-107	-94.43	-78.39	-67.36	-80.01	-67.27	-46.74	-33.80	-21.84
Float	-	-	-	-	40,047	-	-	-	43,102	-	-	-	107,317	-	-	-	85,818	-	-	-	15,369	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	3.7%	-1,200	-1,245	-1,053	-1,023	-2,003	-1,057	-1,141	-2,293	-1,507	-404	-1,558	-1,102	-967	-638	-2,234	-3,139	-972	-503	-653	-402	-220
Share Based Compensation	-11.4%	314	354	320	404	389	401	400	392	305	292	192	194	114	474	18.00	28.00	31.00	37.00	45.00	45.00	57.00
Cashflow From Investing	489.7%	2,004	-514	-475	2,449	-4,431	-4.70	-3.91	85*	-	4.00	-6.41	-7.16	-5.92	-	-5.94	-8.36	-7.14	-	-1.81	-	-8.10
Cashflow From Financing	-90.6%	241	2,567	-2.16	-2.16	-2.16	-2.06	-2.25	-2.17	-2.06	674	79.00	136	3,701	414	79.00	18,992	229	309	29.00	1*	2,225

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MLSS Income Statement

2024-03-31

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Product sales, net	$ 2,248,845	$ 2,597,598
Cost of products sold	572,742	708,135
Gross profit	1,676,103	1,889,463
Selling, general and administrative expenses	3,035,276	3,074,572
Research and development expenses	94,211	140,347
Depreciation and amortization expense	11,684	17,220
Total operating expenses	3,141,171	3,232,139
Loss from operations	(1,465,068)	(1,342,676)
Interest income (expense)	(3,351)	23,345
Unrealized Gain Treasury investment	27,890	0
Loss before provision for income taxes	(1,440,529)	(1,319,331)
Provision for income taxes	0	0
Net loss	(1,440,529)	(1,319,331)
Net loss attributable to noncontrolling interests	0	(11,665)
Net loss attributable to Milestone Scientific Inc.	$ (1,440,529)	$ (1,307,666)
Net loss per share applicable to common stockholders—
Basic and Diluted (in dollars per share)	$ (0.02)	$ (0.02)
Weighted average shares outstanding and to be issued—
Basic and Diluted (in shares)	79,738,551	72,104,234

MLSS Balance Sheet

2024-03-31

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,005,477	$ 2,977,713
Marketable securities	1,000,000	2,976,573
Accounts receivable, net of allowance for credit losses of $10,000, respectively	661,838	312,664
Prepaid expenses and other current assets	863,589	517,785
Inventories	2,860,029	2,638,186
Advances on contracts	1,421,120	1,371,548
Total current assets	10,812,053	10,794,469
Furniture, fixtures and equipment, net	8,023	10,024
Intangibles, net	168,956	178,636
Right of use assets finance lease	6,835	8,998
Right of use assets operating lease	330,769	355,235
Other assets	24,150	24,150
Total assets	11,350,786	11,371,512
Current liabilities:
Accrued expenses and other payables	1,241,403	1,511,717
Accrued expenses, related party	170,720	137,189
Accrued Liabilities noncontrolling interest	214,000	214,000
Current portion of finance lease liabilities	8,219	10,264
Current portion of operating lease liabilities	107,355	103,427
Total current liabilities	3,636,603	3,076,713
Non-current portion of finance lease liabilities	0	434
Non-current portion of operating lease liabilities	253,774	281,853
Total liabilities	3,890,377	3,359,000
Commitments
Stockholders’ equity
Common stock, par value $0.001; authorized 100,000,000 shares; 76,632,279 shares issued and 76,598,946 shares outstanding as of March 31, 2024 shares; 75,881,840 shares issued and 75,848,507 shares outstanding as of December 31, 2023;	76,632	75,881
Additional paid in capital	133,075,331	132,187,656
Accumulated deficit	(124,780,038)	(123,339,509)
Treasury stock, at cost, 33,333 shares	(911,516)	(911,516)
Total Milestone Scientific, Inc. stockholders' equity	7,460,409	8,012,512
Total liabilities and stockholders’ equity	11,350,786	11,371,512
Nonrelated Party [Member]
Current liabilities:
Accounts payable	1,105,589	689,604
Related Party [Member]
Current liabilities:
Accounts payable	$ 789,317	$ 410,512

About Milestone Scientific Inc

Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.

CEO	Mr. Jan Adriaan Haverhals
WEBSITE	milestonescientific.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	20

Milestone Scientific Inc Frequently Asked Questions

What is the ticker symbol for Milestone Scientific Inc? What does MLSS stand for in stocks?

MLSS is the stock ticker symbol of Milestone Scientific Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Milestone Scientific Inc (MLSS)?

As of Fri May 17 2024, market cap of Milestone Scientific Inc is 54.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MLSS stock?

You can check MLSS's fair value in chart for subscribers.

What is the fair value of MLSS stock?

You can check MLSS's fair value in chart for subscribers. The fair value of Milestone Scientific Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Milestone Scientific Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MLSS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Milestone Scientific Inc a good stock to buy?

The fair value guage provides a quick view whether MLSS is over valued or under valued. Whether Milestone Scientific Inc is cheap or expensive depends on the assumptions which impact Milestone Scientific Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MLSS.

What is Milestone Scientific Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MLSS's PE ratio (Price to Earnings) is -7.65 and Price to Sales (PS) ratio is 5.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MLSS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Milestone Scientific Inc's stock?

In the past 10 years, Milestone Scientific Inc has provided -0.083 (multiply by 100 for percentage) rate of return.